|
AR077468A1
(es)
|
2009-07-09 |
2011-08-31 |
Array Biopharma Inc |
Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
WO2013006486A2
(en)
|
2011-07-01 |
2013-01-10 |
Ngm Biopharmaceuticals, Inc. |
Compositions, uses and methods for treatment of metabolic disorders and diseases
|
|
ES2704744T3
(es)
|
2012-06-13 |
2019-03-19 |
Incyte Holdings Corp |
Compuestos tricíclicos sustituidos como inhibidores de FGFR
|
|
SMT202100451T1
(it)
*
|
2012-07-11 |
2021-09-14 |
Blueprint Medicines Corp |
Inibitori del recettore di crescita dei fibroblasti
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
HK1214832A1
(zh)
|
2012-11-28 |
2016-08-05 |
恩格姆生物制药公司 |
用於代謝病症和疾病治療的組合物和方法
|
|
US9290557B2
(en)
|
2012-11-28 |
2016-03-22 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants and fusions of FGF19 polypeptides
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
MX383664B
(es)
|
2012-12-27 |
2025-03-14 |
Ngm Biopharmaceuticals Inc |
Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares.
|
|
US9273107B2
(en)
|
2012-12-27 |
2016-03-01 |
Ngm Biopharmaceuticals, Inc. |
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
AR094812A1
(es)
|
2013-02-20 |
2015-08-26 |
Eisai R&D Man Co Ltd |
Derivado de piridina monocíclico como inhibidor del fgfr
|
|
UY35464A
(es)
|
2013-03-15 |
2014-10-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
|
MY181020A
(en)
|
2013-03-15 |
2020-12-16 |
Sanofi Sa |
Heteroaryl compounds and uses thereof
|
|
WO2014160521A1
(en)
|
2013-03-15 |
2014-10-02 |
Blueprint Medicines Corporation |
Piperazine derivatives and their use as kit modulators
|
|
TWI647220B
(zh)
|
2013-03-15 |
2019-01-11 |
美商西建卡爾有限責任公司 |
雜芳基化合物及其用途
|
|
EA035095B1
(ru)
|
2013-04-19 |
2020-04-27 |
Инсайт Холдингс Корпорейшн |
Бициклические гетероциклы в качестве ингибиторов fgfr
|
|
EP3019491A4
(en)
|
2013-07-09 |
2016-12-21 |
Dana Farber Cancer Inst Inc |
KINASEHEMMER FOR THE TREATMENT OF DISEASES
|
|
AU2014308616B2
(en)
|
2013-08-23 |
2018-12-06 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Ｋｒａｓ ｇ１２ｃ之抑制劑
|
|
MX365614B
(es)
|
2013-10-17 |
2019-06-07 |
Blueprint Medicines Corp |
Composiciones utiles para tratar trastornos relacionados con kit.
|
|
MX378288B
(es)
|
2013-10-18 |
2025-03-10 |
Eisai R&D Man Co Ltd |
Inhibidores de pirimidina del fgfr4.
|
|
CA2928042C
(en)
*
|
2013-10-25 |
2022-05-10 |
Blueprint Medicines Corporation |
Inhibitors of the fibroblast growth factor receptor
|
|
CN105683188B
(zh)
|
2013-10-25 |
2018-02-09 |
诺华股份有限公司 |
作为fgfr4抑制剂的稠环二环吡啶基衍生物
|
|
WO2015065897A1
(en)
|
2013-10-28 |
2015-05-07 |
Ngm Biopharmaceuticals, Inc. |
Cancer models and associated methods
|
|
WO2015108992A1
(en)
|
2014-01-15 |
2015-07-23 |
Blueprint Medicines Corporation |
Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
|
|
AU2015206292B2
(en)
|
2014-01-20 |
2018-02-15 |
Cleave Biosciences, Inc. |
Fused pyrimidines as inhibitors of p97 complex
|
|
PT3097122T
(pt)
|
2014-01-24 |
2020-07-21 |
Ngm Biopharmaceuticals Inc |
Anticorpos de ligação de domínio 2 de beta klotho e métodos de utilização dos mesmos
|
|
MX369369B
(es)
*
|
2014-02-07 |
2019-11-06 |
Principia Biopharma Inc |
Derivados de quinolona como inhibidores del receptor del factor de crecimiento de fibroblastos.
|
|
US9932329B2
(en)
|
2014-03-03 |
2018-04-03 |
Principia Biopharma, Inc. |
Benzimidazole derivatives as RLK and ITK inhibitors
|
|
MA38393B1
(fr)
*
|
2014-03-13 |
2018-11-30 |
Sanofi Sa |
Composés hétéroaryle et utilisations associées
|
|
US10398758B2
(en)
|
2014-05-28 |
2019-09-03 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
|
|
WO2015195509A2
(en)
|
2014-06-16 |
2015-12-23 |
Ngm Biopharmaceuticals, Inc. |
Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
CN105017227B
(zh)
*
|
2014-07-08 |
2018-03-09 |
四川百利药业有限责任公司 |
N‑(1h‑吡唑‑5‑基)喹唑啉‑4‑胺类化合物
|
|
KR102344105B1
(ko)
|
2014-08-18 |
2021-12-29 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
모노시클릭 피리딘 유도체의 염 및 이의 결정
|
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
JP6585167B2
(ja)
|
2014-10-03 |
2019-10-02 |
ノバルティス アーゲー |
Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
CN114129709A
(zh)
|
2014-10-23 |
2022-03-04 |
恩格姆生物制药公司 |
包含肽变异体的药物组合物及其使用方法
|
|
US10434144B2
(en)
|
2014-11-07 |
2019-10-08 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
|
|
WO2016115412A1
(en)
*
|
2015-01-18 |
2016-07-21 |
Newave Pharmaceutical Llc |
Dual-warhead covalent inhibitors of fgfr-4
|
|
US10202365B2
(en)
|
2015-02-06 |
2019-02-12 |
Blueprint Medicines Corporation |
2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
|
|
CN107613769A
(zh)
*
|
2015-02-17 |
2018-01-19 |
润新生物公司 |
某些化学实体、组合物和方法
|
|
MA41551A
(fr)
*
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
|
MX373169B
(es)
|
2015-02-20 |
2020-04-24 |
Incyte Holdings Corp |
Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
|
|
US9802917B2
(en)
|
2015-03-25 |
2017-10-31 |
Novartis Ag |
Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
|
|
RU2017134379A
(ru)
|
2015-03-25 |
2019-04-03 |
Новартис Аг |
Формилированные n-гетероциклические производные в качестве ингибиторов fgfr4
|
|
ES2887148T3
(es)
|
2015-03-25 |
2021-12-21 |
Nat Cancer Ct |
Agente terapéutico contra el cáncer de vías biliares
|
|
JP2018513853A
(ja)
|
2015-04-10 |
2018-05-31 |
アラクセス ファーマ エルエルシー |
置換キナゾリン化合物およびその使用方法
|
|
SG10201810057UA
(en)
|
2015-04-14 |
2018-12-28 |
Eisai R&D Man Co Ltd |
Crystalline fgfr4 inhibitor compound and uses thereof
|
|
JP6789239B2
(ja)
|
2015-04-15 |
2020-11-25 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法
|
|
US10538517B2
(en)
|
2015-05-22 |
2020-01-21 |
Principia Biopharma, Inc. |
Quinolone derivatives as FGFR inhibitors
|
|
UA124090C2
(uk)
|
2015-06-03 |
2021-07-21 |
Прінсіпіа Байофарма Інк. |
Інгібітори тирозинкінази
|
|
BR112018000808A2
(pt)
|
2015-07-16 |
2018-09-04 |
Array Biopharma Inc |
compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
WO2017019442A1
(en)
|
2015-07-24 |
2017-02-02 |
Blueprint Medicines Corporation |
Compounds useful for treating disorders related to kit and pdgfr
|
|
WO2017019957A2
(en)
|
2015-07-29 |
2017-02-02 |
Ngm Biopharmaceuticals, Inc. |
Binding proteins and methods of use thereof
|
|
JP6940480B2
(ja)
|
2015-08-11 |
2021-09-29 |
プリンシピア バイオファーマ インコーポレイテッド |
Ｆｇｆｒ阻害剤の合成方法
|
|
AU2016311426B2
(en)
|
2015-08-26 |
2021-05-20 |
Blueprint Medicines Corporation |
Compounds and compositions useful for treating disorders related to NTRK
|
|
US10647703B2
(en)
|
2015-09-28 |
2020-05-12 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
US10882847B2
(en)
|
2015-09-28 |
2021-01-05 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058807A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356354A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356353A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
AU2016341445B2
(en)
*
|
2015-10-23 |
2020-08-27 |
Array Biopharma, Inc. |
2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
|
|
CN108697708A
(zh)
|
2015-10-26 |
2018-10-23 |
洛克索肿瘤学股份有限公司 |
Trk抑制剂抗性癌症中的点突变以及与此相关的方法
|
|
PL3371171T3
(pl)
|
2015-11-02 |
2024-03-25 |
Blueprint Medicines Corporation |
Inhibitory RET
|
|
JP6728352B2
(ja)
|
2015-11-09 |
2020-07-22 |
エヌジーエム バイオファーマシューティカルス，インコーポレーテッド |
胆汁酸に関係した障害の治療方法
|
|
KR20180081596A
(ko)
|
2015-11-16 |
2018-07-16 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
|
MX2018006195A
(es)
|
2015-11-19 |
2018-09-05 |
Blueprint Medicines Corp |
Compuestos y composiciones utiles para el tratamiento de trastornos relacionados con ntrk.
|
|
US12414945B2
(en)
|
2015-12-17 |
2025-09-16 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for breast cancer
|
|
CN105669566A
(zh)
*
|
2016-03-09 |
2016-06-15 |
华东师范大学 |
一种医药中间体n-芳基喹唑啉-2-胺化合物的制备方法
|
|
TW201738228A
(zh)
|
2016-03-17 |
2017-11-01 |
藍圖醫藥公司 |
Ｒｅｔ之抑制劑
|
|
RS65988B1
(sr)
|
2016-04-04 |
2024-10-31 |
Loxo Oncology Inc |
Postupak lečenja pedijatrijskih karcinoma
|
|
US10045991B2
(en)
|
2016-04-04 |
2018-08-14 |
Loxo Oncology, Inc. |
Methods of treating pediatric cancers
|
|
ES2987474T3
(es)
|
2016-04-04 |
2024-11-15 |
Loxo Oncology Inc |
Formulaciones líquidas de (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-IL)-pirazolo[1,5-A]pirimidin-3-IL)-3-hidroxipirrolidina-1-carboxamida
|
|
SG11201808907PA
(en)
|
2016-04-15 |
2018-11-29 |
Blueprint Medicines Corp |
Inhibitors of activin receptor-like kinase
|
|
EP3454898B1
(en)
|
2016-05-10 |
2021-11-10 |
Eisai R&D Management Co., Ltd. |
Drug combinations for reducing cell viability and/or cell proliferation
|
|
ES2836222T3
(es)
|
2016-05-18 |
2021-06-24 |
Loxo Oncology Inc |
Preparación de (S)-N-(5-((R)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
|
|
WO2018004258A1
(ko)
*
|
2016-06-28 |
2018-01-04 |
한미약품 주식회사 |
신규한 헤테로시클릭 유도체 화합물 및 이의 용도
|
|
KR20180002053A
(ko)
|
2016-06-28 |
2018-01-05 |
한미약품 주식회사 |
신규한 헤테로시클릭 유도체 화합물 및 이의 용도
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
US10227329B2
(en)
|
2016-07-22 |
2019-03-12 |
Blueprint Medicines Corporation |
Compounds useful for treating disorders related to RET
|
|
WO2018022761A1
(en)
|
2016-07-27 |
2018-02-01 |
Blueprint Medicines Corporation |
Substituted cyclopentane-amides for treating disorders related to ret
|
|
CN109843858B
(zh)
|
2016-08-15 |
2023-05-05 |
润新生物公司 |
某些化学实体、组合物及方法
|
|
EP3503882A4
(en)
|
2016-08-26 |
2020-07-29 |
NGM Biopharmaceuticals, Inc. |
METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS
|
|
US10744139B2
(en)
|
2016-09-01 |
2020-08-18 |
Nanjing Transthera Biosciences Co. Ltd. |
Inhibitors of fibroblast growth factor receptor and use thereof
|
|
WO2018049233A1
(en)
|
2016-09-08 |
2018-03-15 |
Nicolas Stransky |
Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
|
|
WO2018055503A1
(en)
|
2016-09-20 |
2018-03-29 |
Novartis Ag |
Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
|
|
US10280172B2
(en)
|
2016-09-29 |
2019-05-07 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
|
EP3523289A1
(en)
|
2016-10-07 |
2019-08-14 |
Araxes Pharma LLC |
Heterocyclic compounds as inhibitors of ras and methods of use thereof
|
|
TWI752098B
(zh)
|
2016-10-10 |
2022-01-11 |
美商亞雷生物製藥股份有限公司 |
作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
|
|
TWI704148B
(zh)
|
2016-10-10 |
2020-09-11 |
美商亞雷生物製藥股份有限公司 |
作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
|
|
WO2018072707A1
(zh)
*
|
2016-10-18 |
2018-04-26 |
保诺科技（北京）有限公司 |
芳香族醚类衍生物、其制备方法及其在医药上的应用
|
|
JOP20190092A1
(ar)
|
2016-10-26 |
2019-04-25 |
Array Biopharma Inc |
عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
|
|
SG11201903911UA
(en)
|
2016-11-02 |
2019-05-30 |
Novartis Ag |
Combinations of fgfr4 inhibitors and bile acid sequestrants
|
|
NZ754218A
(en)
*
|
2016-11-17 |
2021-07-30 |
Guangdong Zhongsheng Pharmaceutical Co Ltd |
Fgfr4 inhibitor and preparation method and use thereof
|
|
KR101812266B1
(ko)
|
2016-11-25 |
2017-12-27 |
한국과학기술연구원 |
4-((2-아크릴아미도페닐)아미노)티에노[3,2-d]피리미딘-7-카복스아미드 유도체 및 그의 약학적 활용
|
|
DK3524603T3
(da)
|
2016-12-19 |
2022-07-04 |
Abbisko Therapeutics Co Ltd |
Fgfr4-hæmmer, fremgangsmåde til fremstilling deraf og farmaceutisk anvendelse deraf
|
|
CN108239069B
(zh)
*
|
2016-12-26 |
2021-01-05 |
南京药捷安康生物科技有限公司 |
一种用于成纤维细胞生长因子受体的抑制剂及其用途
|
|
CN108264511B
(zh)
*
|
2017-01-03 |
2021-04-13 |
浙江海正药业股份有限公司 |
杂环类衍生物及其制备方法和其在医药上的用途
|
|
US11168090B2
(en)
|
2017-01-18 |
2021-11-09 |
Array Biopharma Inc. |
Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
|
|
WO2018136663A1
(en)
|
2017-01-18 |
2018-07-26 |
Array Biopharma, Inc. |
Ret inhibitors
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
WO2018140513A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
WO2018140514A1
(en)
*
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
|
|
CN110382482A
(zh)
|
2017-01-26 |
2019-10-25 |
亚瑞克西斯制药公司 |
稠合的杂-杂二环化合物及其使用方法
|
|
CN108503593B
(zh)
*
|
2017-02-28 |
2021-04-27 |
暨南大学 |
2-氨基嘧啶类化合物及其应用
|
|
JOP20190213A1
(ar)
|
2017-03-16 |
2019-09-16 |
Array Biopharma Inc |
مركبات حلقية ضخمة كمثبطات لكيناز ros1
|
|
US11040979B2
(en)
|
2017-03-31 |
2021-06-22 |
Blueprint Medicines Corporation |
Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
|
|
US11639346B2
(en)
|
2017-05-25 |
2023-05-02 |
Araxes Pharma Llc |
Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
|
|
JP2020521741A
(ja)
|
2017-05-25 |
2020-07-27 |
アラクセス ファーマ エルエルシー |
がんの処置のための化合物およびその使用の方法
|
|
AU2018271990A1
(en)
|
2017-05-25 |
2019-12-12 |
Araxes Pharma Llc |
Covalent inhibitors of KRAS
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
EP3444275A1
(en)
|
2017-08-16 |
2019-02-20 |
Exiris S.r.l. |
Monoclonal antibody anti-fgfr4
|
|
WO2019047826A1
(zh)
|
2017-09-05 |
2019-03-14 |
博奥阿迪斯生物科技公司 |
芳香类衍生物、其制备方法及其在医药上的应用
|
|
TWI812649B
(zh)
|
2017-10-10 |
2023-08-21 |
美商絡速藥業公司 |
6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
|
|
TWI791053B
(zh)
|
2017-10-10 |
2023-02-01 |
美商亞雷生物製藥股份有限公司 |
6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
|
|
WO2019079649A1
(en)
|
2017-10-18 |
2019-04-25 |
Blueprint Medicines Corporation |
SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-RELATED KINASE
|
|
KR20190043437A
(ko)
|
2017-10-18 |
2019-04-26 |
씨제이헬스케어 주식회사 |
단백질 키나제 억제제로서의 헤테로고리 화합물
|
|
KR20240152947A
(ko)
|
2017-10-18 |
2024-10-22 |
인사이트 코포레이션 |
Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체
|
|
WO2019085894A1
(zh)
*
|
2017-10-30 |
2019-05-09 |
如东凌达生物医药科技有限公司 |
一类含氮稠环化合物及其制备方法和用途
|
|
WO2019143991A1
(en)
|
2018-01-18 |
2019-07-25 |
Array Biopharma Inc. |
SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
|
|
EP3740491A1
(en)
|
2018-01-18 |
2020-11-25 |
Array Biopharma, Inc. |
Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
|
|
CN111615514B
(zh)
|
2018-01-18 |
2022-10-11 |
奥瑞生物药品公司 |
作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
|
|
JP7168149B2
(ja)
*
|
2018-02-08 |
2022-11-09 |
▲ザン▼州片仔▲ファン▼薬業股▲フン▼有限公司 |
Ｆｇｆｒ阻害剤としてのピラジン－２（１ｈ）－オン系化合物
|
|
SG11202007591RA
(en)
|
2018-03-28 |
2020-09-29 |
Eisai R&D Man Co Ltd |
Therapeutic agent for hepatocellular carcinoma
|
|
SI3773589T1
(sl)
|
2018-04-03 |
2024-03-29 |
Blueprint Medicines Corporation |
Inhibitor RET za uporabo pri zdravljenju raka, ki ima RET spremembo
|
|
CN110386921A
(zh)
*
|
2018-04-23 |
2019-10-29 |
南京药捷安康生物科技有限公司 |
成纤维细胞生长因子受体抑制剂化合物
|
|
CR20200590A
(es)
|
2018-05-04 |
2021-04-26 |
Incyte Corp |
Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
|
|
MA52493A
(fr)
|
2018-05-04 |
2021-03-10 |
Incyte Corp |
Sels d'un inhibiteur de fgfr
|
|
WO2019223766A1
(zh)
*
|
2018-05-25 |
2019-11-28 |
上海和誉生物医药科技有限公司 |
一种fgfr抑制剂、其制备方法和在药学上的应用
|
|
CN110577524B
(zh)
*
|
2018-06-07 |
2022-01-28 |
北京大学深圳研究生院 |
一种激酶选择性抑制剂
|
|
CN112313207B
(zh)
*
|
2018-06-22 |
2023-02-14 |
北京赛特明强医药科技有限公司 |
一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用
|
|
US12109193B2
(en)
|
2018-07-31 |
2024-10-08 |
Loxo Oncology Inc. |
Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide
|
|
MX2021000887A
(es)
|
2018-08-01 |
2021-03-31 |
Araxes Pharma Llc |
Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
|
|
CR20250050A
(es)
|
2018-09-05 |
2025-03-19 |
Incyte Corp |
Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
|
|
EP3849986B1
(en)
|
2018-09-10 |
2022-06-08 |
Array Biopharma, Inc. |
Fused heterocyclic compounds as ret kinase inhibitors
|
|
RU2771526C1
(ru)
*
|
2018-09-14 |
2022-05-05 |
Аббиско Терапеутикс Ко., Лтд. |
Ингибитор fgfr, метод его получения и его применение
|
|
CN110950867A
(zh)
*
|
2018-09-27 |
2020-04-03 |
首药控股(北京)有限公司 |
一种fgfr4激酶抑制剂及其制备方法和用途
|
|
CN111138459B
(zh)
*
|
2018-11-06 |
2022-10-18 |
南京圣和药业股份有限公司 |
Fgfr4抑制剂的光学异构体及其应用
|
|
KR102195348B1
(ko)
|
2018-11-15 |
2020-12-24 |
에이치케이이노엔 주식회사 |
단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
|
|
WO2020119606A1
(en)
*
|
2018-12-10 |
2020-06-18 |
Guangdong Newopp Biopharmaceuticals Co., Ltd. |
Heterocyclic compounds as inhibitors of fibroblast growth factor receptor
|
|
WO2020131627A1
(en)
|
2018-12-19 |
2020-06-25 |
Array Biopharma Inc. |
Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
|
|
EP3898615A1
(en)
|
2018-12-19 |
2021-10-27 |
Array Biopharma, Inc. |
7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
|
|
WO2020177067A1
(en)
*
|
2019-03-05 |
2020-09-10 |
Bioardis Llc |
Aromatic derivatives, preparation methods, and medical uses thereof
|
|
EP3936509B1
(en)
*
|
2019-03-08 |
2024-07-31 |
Shouyao Holdings (Beijing) Co., Ltd. |
Fgfr4 kinase inhibitor, preparation method therefor and use thereof
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
WO2020210669A1
(en)
|
2019-04-12 |
2020-10-15 |
Blueprint Medicines Corporation |
Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making
|
|
CN110317176A
(zh)
*
|
2019-07-04 |
2019-10-11 |
沈阳药科大学 |
2-氨基嘧啶类化合物及其用途
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
KR102753831B1
(ko)
*
|
2019-07-26 |
2025-01-14 |
씨젠테크 (쑤저우, 차이나) 컴퍼니 리미티드 |
Fgfr 및 vegfr 이중 억제제로서의 피리딘 유도체
|
|
US11535609B2
(en)
|
2019-08-08 |
2022-12-27 |
Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. |
Pyrazine-2(1H)-ketone compound preparation method
|
|
CN114174270B
(zh)
*
|
2019-08-08 |
2023-06-06 |
漳州片仔癀药业股份有限公司 |
吡嗪-2(1h)-酮类化合物的a晶型和b晶型及其制备方法
|
|
WO2021023195A1
(zh)
*
|
2019-08-08 |
2021-02-11 |
漳州片仔癀药业股份有限公司 |
吡嗪-2（1h）-酮类化合物的d晶型及其制备方法
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
TWI891666B
(zh)
|
2019-10-14 |
2025-08-01 |
美商英塞特公司 |
作為ｆｇｆｒ抑制劑之雙環雜環
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CN112759593A
(zh)
|
2019-11-01 |
2021-05-07 |
北京伯汇生物技术有限公司 |
桥环并醛基吡啶衍生物及其应用
|
|
EP4069696A1
(en)
|
2019-12-04 |
2022-10-12 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
BR112022010664A2
(pt)
|
2019-12-04 |
2022-08-16 |
Incyte Corp |
Derivados de um inibidor de fgfr
|
|
EP4069369A4
(en)
|
2019-12-06 |
2024-02-14 |
Schrödinger, Inc. |
CYCLIC COMPOUNDS AND METHODS OF USE
|
|
EP4083021B1
(en)
|
2019-12-23 |
2025-07-02 |
Beijing Scitech-MQ Pharmaceuticals Limited |
Cyano-substituted pyridine and cyano-substituted pyrimidine compound and preparation method therefor and application thereof
|
|
IL294214B2
(en)
|
2019-12-27 |
2026-04-01 |
Schrodinger Inc |
Cyclic compounds and methods for using them
|
|
WO2021146424A1
(en)
*
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
JP2023527412A
(ja)
|
2020-05-29 |
2023-06-28 |
ブループリント メディシンズ コーポレイション |
プラルセチニブの固体形態
|
|
EP4161657A1
(en)
*
|
2020-06-05 |
2023-04-12 |
Kinnate Biopharma Inc. |
Inhibitors of fibroblast growth factor receptor kinases
|
|
JP2023541047A
(ja)
|
2020-09-10 |
2023-09-27 |
シュレーディンガー， インコーポレイテッド |
がんの治療のための複素環式ペリ縮環ｃｄｃ７キナーゼ阻害剤
|
|
CN112851587A
(zh)
*
|
2021-01-21 |
2021-05-28 |
药雅科技(上海)有限公司 |
一种用于治疗癌症的炔类杂环化合物及其制备方法与用途
|
|
CA3206502A1
(en)
*
|
2021-01-26 |
2022-08-04 |
Zhengxia CHEN |
Crystal form of methylpyrazole-substituted pyridoimidazole compound and preparation method therefor
|
|
EP4284804A1
(en)
|
2021-01-26 |
2023-12-06 |
Schrödinger, Inc. |
Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders
|
|
CN114853740B
(zh)
*
|
2021-02-03 |
2023-08-01 |
药雅科技(上海)有限公司 |
炔类嘧啶化合物作为fgfr抑制剂的制备方法和用途
|
|
AR125588A1
(es)
*
|
2021-03-04 |
2023-08-02 |
Lilly Co Eli |
Compuestos inhibidores de fgfr3
|
|
WO2022194160A1
(zh)
*
|
2021-03-16 |
2022-09-22 |
上海启晟合研医药科技有限公司 |
非索替尼固体形式及其制备方法
|
|
TW202300150A
(zh)
|
2021-03-18 |
2023-01-01 |
美商薛定諤公司 |
環狀化合物及其使用方法
|
|
AU2021436754B2
(en)
*
|
2021-03-26 |
2024-11-07 |
Apeloa Pharmaceutical Co., Ltd. |
Bicyclic heterocyclic fgfr4 inhibitor, pharmaceutical composition and preparation comprising same, and application thereof
|
|
TW202304459A
(zh)
|
2021-04-12 |
2023-02-01 |
美商英塞特公司 |
包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
|
|
WO2022261159A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
EP4352059A1
(en)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
CN113912602B
(zh)
*
|
2021-10-14 |
2023-05-05 |
温州医科大学 |
一种2-氧代-1,2-二氢-1,6-萘啶-7-基类化合物及其制备方法和用途
|
|
WO2024242495A1
(ko)
*
|
2023-05-25 |
2024-11-28 |
주식회사 매직불릿테라퓨틱스 |
단백질 키나아제 억제용 신규 화합물 및 이를 포함하는 약학조성물
|
|
TWI896159B
(zh)
*
|
2023-06-09 |
2025-09-01 |
大陸商上海和譽生物醫藥科技有限公司 |
一種fgfr4抑制劑組合物、其製備方法和在藥學上的應用
|
|
EP4509142A1
(en)
|
2023-08-16 |
2025-02-19 |
Ona Therapeutics S.L. |
Fgfr4 as target in cancer treatment
|
|
WO2025059027A1
(en)
|
2023-09-11 |
2025-03-20 |
Schrödinger, Inc. |
Cyclopenta[e]pyrazolo[1,5-a]pyrimidine derivatives as malt1 inhibitors
|